FDA Clears Golimumab Biosimilars - Top-Institutions - MDSpire

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.

  • By

  • Kathryn Wighton

  • May 18, 2026

  • 2 min

Share

Top Institutions in Rheumatology

Brief introduction explaining scope and methodology.

  • #1

    The Johns Hopkins Hospital
    The Johns Hopkins Hospital

    Baltimore, Maryland

    Key Differentiators

    • Rheumatology

  • #2

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, Ohio

    Key Differentiators

    • Rheumatology

Original Source(s)

FDA Clears Golimumab Biosimilars

  • by Kathryn Wighton

  • May 18, 2026

Related Content

Neutrophil extracellular traps and pyroptosis: a molecular nexus linking systemic autoimmune diseases to atherosclerosis

CAR T Cells Target TNF in Mouse Model of Rheumatoid Arthritis

A single infusion of engineered T cells degraded soluble TNF and produced durable disease control in mice

  • June 30, 2026

  • 3 min
IL-34-mediated fibroblast-like synoviocyte-macrophage crosstalk drives bone erosion in rheumatoid arthritis through RANKL-dependent osteoclastogenesis